ArticleBritish journal of cancer2001
Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer.British journal of cancer · 2002Trial
- Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer.Scientific reports · 2025Article
- Harnessing Exosomes: A Brief Overview of Nature's Nanocarriers and a Glimpse into Their Implications in Pituitary Neuroendocrine Tumors (PitNETs).Current issues in molecular biology · 2025Review
- Exosomes in the tumor microenvironment: Promoting cancer progression.Frontiers in immunology · 2022Review
- Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions.Scientific reports · 2020Article
- Defects at the Posttranscriptional Level Account for the Low TCRJournal of immunology research · 2020Article
- Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets.Scientific reports · 2016Article
- Extracellular 2'5'-oligoadenylate synthetase 2 mediates T-cell receptor CD3-ζ chain down-regulation via caspase-3 activation in oral cancer.Immunology · 2016Article
- Covert operations: cancer's many subversive tactics in overcoming host defenses.Transactions of the American Clinical and Climatological Association · 2013Article
- Epigenetic biomarkers of T-cells in human glioma.Epigenetics · 2012Article
- The mechanisms by which polyamines accelerate tumor spread.Journal of experimental & clinical cancer research : CR · 2011Review
- Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments.Seminars in immunopathology · 2011Review
- The detection, treatment, and biology of epithelial ovarian cancer.Journal of ovarian research · 2010Article
- Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients.Clinical and experimental immunology · 2009Article
- Increased blood spermine levels decrease the cytotoxic activity of lymphokine-activated killer cells: a novel mechanism of cancer evasion.Cancer immunology, immunotherapy : CII · 2007Article
- Expression of CD45 and proliferative response to CD3 as suitable classification markers of patients with gastric adenocarcinoma.Cancer immunology, immunotherapy : CII · 2006Article
- Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?Cancer immunology, immunotherapy : CII · 2004Review
- Intrinsic defects explain altered proliferative responses of T lymphocytes and HVS-derived T-cell lines in gastric adenocarcinoma.Cancer immunology, immunotherapy : CII · 2003Article
- Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer.British journal of cancer · 2003Article
- Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck.British journal of cancer · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In women with ovarian cancer, suppression of components of the immune system may promote tumour development. Previous studies in ovarian cancer have demonstrated that decreased expression and function of the T-cell receptor (TcR)-associated signal transducing zeta-chain correlates with deficient immune responsiveness of T cells. In this study, sera and ascitic fluids obtained from woman with advanced ovarian cancer were found to suppress the expression of TcR-associated zeta chain. This suppression of zeta chain expression was dose-dependent and was not observed with biologic fluids obtained from healthy women. The factor responsible for the loss of zeta chain was purified from ascites and characterized as a protein with an appropriate molecular weight of 14 kD. Suppression of T-cell TcR-zeta was specific, since neither lck nor ZAP-70 expression was affected, while zeta chain was almost completely suppressed. This selective suppression of TcR-zeta expression by the 14 kD ascites-derived factor was shown to operate at the mRNA level. By defining the mechanism through which this protein modulates TcR-zeta chain levels, it might be possible to ultimately prevent the suppressive influences of the tumour microenvironment and restor immune competence in patients with ovarian carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.